WO2012083397A8 - Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire - Google Patents

Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire Download PDF

Info

Publication number
WO2012083397A8
WO2012083397A8 PCT/BR2011/000480 BR2011000480W WO2012083397A8 WO 2012083397 A8 WO2012083397 A8 WO 2012083397A8 BR 2011000480 W BR2011000480 W BR 2011000480W WO 2012083397 A8 WO2012083397 A8 WO 2012083397A8
Authority
WO
WIPO (PCT)
Prior art keywords
guanabenz
primary cutaneous
treatment
cutaneous amyloidosis
containing compound
Prior art date
Application number
PCT/BR2011/000480
Other languages
English (en)
Other versions
WO2012083397A1 (fr
Inventor
Omar Lupi da Rosa SANTOS
Luis Eduardo Da Cruz
Original Assignee
Silvestre Labs Química E Farmaceutica Ltda.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silvestre Labs Química E Farmaceutica Ltda. filed Critical Silvestre Labs Química E Farmaceutica Ltda.
Priority to PCT/BR2011/000480 priority Critical patent/WO2012083397A1/fr
Priority to BR112013016044A priority patent/BR112013016044A2/pt
Publication of WO2012083397A1 publication Critical patent/WO2012083397A1/fr
Publication of WO2012083397A8 publication Critical patent/WO2012083397A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

La présente invention concerne une composition pharmaceutique avec du guanabenz en tant que substance active et qui est indiquée pour le traitement de l'amyloïdose cutanée primaire. La composition de cette invention peut être fournie sous forme de crème, de gel, de crème gélifiée, de pommade, de lotion ou d'une autre forme pharmaceutique quelconque destinée à une utilisation topique.
PCT/BR2011/000480 2010-12-22 2011-12-20 Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire WO2012083397A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/BR2011/000480 WO2012083397A1 (fr) 2010-12-22 2011-12-20 Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire
BR112013016044A BR112013016044A2 (pt) 2010-12-22 2011-12-20 composto contendo guanabenzeno para tratamento de amiloidose cutânea primária.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI10155082-8 2010-12-22
BR020100119505 2010-12-22
PCT/BR2011/000480 WO2012083397A1 (fr) 2010-12-22 2011-12-20 Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire

Publications (2)

Publication Number Publication Date
WO2012083397A1 WO2012083397A1 (fr) 2012-06-28
WO2012083397A8 true WO2012083397A8 (fr) 2013-07-18

Family

ID=45509166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000480 WO2012083397A1 (fr) 2010-12-22 2011-12-20 Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire

Country Status (1)

Country Link
WO (1) WO2012083397A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
EP3962478A1 (fr) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Méthodes de traitement du prurit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413962B1 (en) 1988-05-02 2002-07-02 N. Eric Naftchi Guanidino compounds effective as anesthetics
WO2001089508A1 (fr) 2000-05-24 2001-11-29 University Of Kentucky Research Foundation Nouveaux sedatifs et analgesiques veterinaires reversibles a action prolongee et leur methode d'utilisation
CN1688299A (zh) * 2002-01-29 2005-10-26 普罗特米克斯公司 抑制细胞毒性蛋白构象异构体
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CA2599718A1 (fr) 2005-03-04 2006-09-08 Acure Pharma Ab Methodes et preparations pharmaceutiques pour le traitement de degats neurologiques
ATE429910T1 (de) * 2006-10-04 2009-05-15 Centre Nat Rech Scient Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen
JP5670196B2 (ja) 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク． 紫斑を治療する組成物および方法

Also Published As

Publication number Publication date
WO2012083397A1 (fr) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012160180A3 (fr) Composition pharmaceutique pour application sur les ongles
CA3006294A1 (fr) Combinaisons de rapamycine et de metformine pour le traitement de maladies articulaires et cutanees
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
WO2014186742A3 (fr) Composition d'hydrogel anhydre
WO2015066647A3 (fr) Liquides ioniques pour administration transdermique de médicaments
WO2012143576A3 (fr) Composés pour prévenir, réduire et/ou soulager des états de démangeaison de la peau
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
MX340985B (es) Compuestos de n-heteroarilo.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
WO2015038533A3 (fr) Modulateur des canaux sodiques pour le traitement de la douleur et du diabète
EP4309735A3 (fr) Composition pharmaceutique de chlorhydrate de s-kétamine
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
EP2275104A3 (fr) Composition pharmaceutique et cosmétique comprenant de la lactoferrine, du ciclopirox et de l'acide étidronique
WO2012154122A3 (fr) Formulation topique pour le traitement de la peau hyperkératosique
BR112012029739A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de infecções microbianas
WO2014060638A8 (fr) Procédé vétérinaire d'atténuation d'aversion au bruit
EP2361083A4 (fr) Composition pour le traitement du tissu épithélial
WO2015001163A3 (fr) Nanoparticules lipidiques pour la cicatrisation de plaies
WO2012083397A8 (fr) Composé contenant du guanabenz pour le traitement de l'amyloïdose cutanée primaire
WO2018094023A3 (fr) Dipeptides cycliques et cicatrisation
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
WO2009147326A8 (fr) Effets analgesiques de la toxine peptidique apetx2
WO2015100348A8 (fr) Réduction des chéloïdes au moyen d'allantoïne topique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11810999

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11810999

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013016044

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 112013016044

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130621